PharmEasy Unicorn

1 lakh+ medicines and health products, with delivery as fast as 4 hours and guaranteed within 24-48 hours, plus COD and online payment options.

Discounts of up to 20% on medicine purchases made through the PharmEasy mobile app.

PharmEasy Corporate Wellness is marketed with "up to 90% savings vs traditional OPD plans" for employers and roughly 30% savings for employees.

Individual patients ordering prescription and OTC medicines, health products, and diagnostic tests for home delivery, fulfilled via a network of partner retail pharmacies across India.

Independent pharmacies and chemists supplied via PharmEasy's B2B distribution arm Ascent, which generated ~60% of group revenue in FY26 (₹4,089 Cr of ₹6,869 Cr).

API Holdings' supply-chain subsidiary Aknamed serves hospitals; company materials cited 1,800+ hospitals and 150,000+ active pharmacies on the platform.

Employers purchasing "PharmEasy Corporate Wellness," a pay-as-you-use employee healthcare plan pitched at HR teams with no upfront cost.

Customers upload prescriptions, which are routed to a nearby partner pharmacy for review before an order is fulfilled, underpinning a trust-based ordering relationship.

Corporates enroll via a dedicated sales channel (corporates@pharmeasy.in) for the Corporate Wellness employee-benefits plan.

A paid subscription relationship (also its own revenue stream) that locks customers into an ongoing account: members get free delivery and cashback credited to their PharmEasy Wallet on subsequent orders, incentivizing repeat-purchase behavior beyond one-off transactions.

Customers can opt in to receive 'Free Doctor Tips' via WhatsApp notifications -- a proactive, always-on engagement and retention touchpoint distinct from the transactional prescription-order relationship.

Primary transacting channel, incentivized with app-exclusive discounts.

Browsing and ordering portal for medicines, diagnostics, and teleconsultations.

Local brick-and-mortar pharmacy network used for order fulfillment across India.

Partnership piloted in Bengaluru for 10-minute medicine delivery, with PharmEasy stores operating inside Swiggy's dark stores.

Prescriptions uploaded by customers are routed to a nearby partner pharmacy before fulfillment.

Coordinating delivery agents and partner pharmacies to fulfill orders within hours.

Ascent procures directly from pharma companies and distributes to retail pharmacies/chemists nationwide.

Operating Thyrocare's diagnostic testing network.

In-house diagnostics capacity via the 66.1%-owned Thyrocare chain, acquired for ₹4,546 Cr in 2021.

67.3%-owned Aknamed provides healthcare-product supply-chain infrastructure serving hospitals.

PharmEasy's own mobile app and website (pharmeasy.in) are the core technology asset the consumer business runs on -- covering prescription upload/verification, ordering, and payments -- backed by a large registered-user and order-history dataset.

In-house and third-party delivery personnel routing orders to the nearest of PharmEasy's 60,000+ partner pharmacies -- the logistics backbone enabling fast doorstep delivery of the consumer ordering experience.

Local pharmacy network for inventory and order fulfillment.

66.1% stake acquired for ₹4,546 Cr in June 2021, giving PharmEasy in-house diagnostics capability.

67.3% controlling stake acquired in September 2021 for hospital/institutional supply-chain distribution.

Shop-in-shop tie-up for 10-minute medicine delivery, piloted in Bengaluru.

Commission/margin earned on sale of prescription and OTC medicines and healthcare products.

Fees from pharmaceutical companies and medical device manufacturers for sponsored placement.

Revenue from virtual consultations with healthcare professionals on the platform.

Monthly-fee membership program bundling discounts/benefits.

Convenience and delivery fees levied on orders.

In-house lab testing revenue via majority-owned Thyrocare.

Wholesale distribution of pharma products to retail pharmacies/chemists.

API Holdings' FY26 opex fell to ₹1,288 Cr (down ~4.5% YoY) despite 14.3% revenue growth, reflecting cost optimization such as reduced discounting.

Legacy loans taken to fund the Thyrocare acquisition (Kotak Mahindra Bank → Goldman Sachs → 360 One NCDs) were reported to carry a high interest rate, weighing on net profitability even after EBITDA turned positive.

Group-wide employee benefit expenses -- including cash salaries and employee stock-based payment charges for staff across the consumer platform, Ascent distribution, Thyrocare, and Aknamed -- rose sharply in FY25, driven mainly by a jump in ESOP charges.

Direct cost of medicines, diagnostic consumables, and other materials sold across the group's consumer, Ascent wholesale-distribution, and Thyrocare diagnostics businesses.

Advertising, promotions, and discount-driven acquisition spend -- historically a major cost line during PharmEasy's growth-stage cash-burn years -- continued to rise even as the group pushed toward EBITDA profitability.